SCHEMBL6830675

SCHEMBL6830675

CON(C)C(=O)Oc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.55
ATM Q13315 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
RAB9A P51151 4/20 0.52
KMT2A Q03164 4/20 0.51
ALDH1A1 P00352 4/20 0.51
PKM P14618 1/20 0.51
MAOB P27338 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
MEN1 O00255 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
BCHE P06276 4/20 0.46
ACHE P22303 4/20 0.46
LMNA P02545 2/20 0.46
GLA P06280 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
NPY5R Q15761 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30439094 0.82 TDP1 (0.57) TDP1ATML3MBTL1RAB9AKMT2A
SCHEMBL11212298 0.81 TDP1 (0.61) TDP1ATML3MBTL1RAB9AKMT2A
Phenyl Dimethylcarbamate SCHEMBL491227 0.81 RAB9A (0.78) TDP1ATML3MBTL1RAB9AKMT2A
SCHEMBL7194185 0.81 TDP1 (0.61) TDP1ATML3MBTL1RAB9AKMT2A
SCHEMBL9858698 0.79 L3MBTL1 (0.50) TDP1ATML3MBTL1RAB9AKMT2A
SCHEMBL12786094 0.79 TDP1 (0.59) TDP1ATML3MBTL1RAB9AKMT2A
SCHEMBL1423356 0.79 ACHE (0.55) TDP1ATML3MBTL1KMT2AALDH1A1
SCHEMBL27806243 0.78 L3MBTL1 (0.49) TDP1ATML3MBTL1RAB9AKMT2A
SCHEMBL11029662 0.78 TDP1 (0.57) TDP1ATML3MBTL1RAB9AKMT2A
Phenyl Dimethylcarbamate SCHEMBL27760797 0.78 RAB9A (0.72) TDP1ATML3MBTL1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743923-B2 A BENZYLIDENE DERIVATIVES USED FOR OSTEOCLAST FORMATION INHIBITION, A NITROGEN MONOXIDE PRODUCTION INHIBITION, AND A TRANSCRIPTION FACTOR NF KAPPA B SUPRESSING AGENT SHIONOGI & CO., LTD. (JP) 2004-06-01 US disclosed
US-20030125364-A1 Antirheumatic agent MATSUMOTO SAICHI (JP) 2003-07-03 US disclosed
US-6525081-B1 Inhibiting osteoclast formation and nitrogen monoxide production; suppressing transcription factor NF kappa B SHIONOGI & CO., LTD. (JP) 2003-02-25 US disclosed
EP-1026162-A1 ANTIRHEUMATIC SHIONOGI & CO., LTD. (JP) 2000-08-09 EP disclosed
EP-0595546-B1 Benzylidene derivatives SHIONOGI & CO (JP) 1996-03-20 EP disclosed
US-5418230-A Antiinflammatory SHIONOGI & CO., LTD. (JP) 1995-05-23 US disclosed
EP-0595546-A1 Benzylidene derivatives SHIONOGI & CO., LTD. (JP) 1994-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125364-A1 Antirheumatic agent IL1A, IL1B, IL17A TDP1 2154/4885ATM 4884/4885L3MBTL1 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.